Macrogenics Inc (MGNX): Lynn Cilinski , VP, Controller and Treasurer of Macrogenics Inc sold 5,000 shares on May 27, 2016. The Insider selling transaction was reported by the company on May 27, 2016 to the Securities and Exchange Commission. The shares were sold at $25.00 per share for a total value of $125,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 4, 2016, Paulo F Costa (director) purchased 10,000 shares at $17.20 per share price.On Jan 6, 2016, Jon Marc Wigginton (Sr VP, Clinical) sold 10,000 shares at $29.64 per share price.Also, On Nov 24, 2015, Lynn Cilinski (VP, Controller and Treasurer) sold 6,921 shares at $35.00 per share price.On Nov 17, 2015, Ezio Bonvini (Senior VP, Research) sold 3,117 shares at $31.44 per share price.
MacroGenics Inc: On Wednesday, May 25, 2016 heightened volatility was witnessed in MacroGenics Inc which led to swings in the share price. The shares opened for trading at $23.8 and hit $24.725 on the upside , eventually ending the session at $24.36, with a gain of 3.84% or 0.9 points. The heightened volatility saw the trading volume jump to 3,49,381 shares. The 52-week high of the share price is $39.9 and the company has a market cap of $842 M . The 52-week low of the share price is at $14.84.
MacroGenics Inc. is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer as well as various autoimmune disorders and infectious diseases. The Company develops new therapeutic product candidates using its antibody-based technology platforms and also in partnership with other biopharmaceutical companies. The Company has a pipeline of product candidates in human clinical testing primarily against various cancers. These include two product candidates developed using Fc Optimization platform namely margetuximab an antibody for the treatment of certain types of metastatic breast cancers and gastroesophageal cancers and MGA271 an antibody to impact various tumors through multiple potential mechanisms of action. In addition the Company has created different product candidates based on Dual-Affinity Re-Targetingr (DART) platform.